Related Experiment Videos
Risk factors of recurrence in 157 MB/PNET patients treated in one institution
D Perek1, M Perek-Polnik, M Drogosiewicz
1Department of Pediatric Oncology, Children's Memorial Health Institute, Warsaw, Poland.
Summary
Recurrence of medulloblastoma/primitive neuroectodermal tumors (MB/PNET) is significantly influenced by the presence of tumor cells in cerebrospinal fluid (CSF). Ensuring adequate chemotherapy doses is crucial for improving patient outcomes and reducing relapse risk.
Area of Science:
- Pediatric Oncology
- Neuro-oncology
- Clinical Research
Background:
- Medulloblastoma/primitive neuroectodermal tumors (MB/PNET) are aggressive brain cancers in children.
- Identifying risk factors for tumor recurrence is critical for improving treatment strategies and patient survival.
Purpose of the Study:
- To evaluate various clinical and treatment-related factors associated with MB/PNET recurrence.
- To determine the prognostic significance of tumor cells in cerebrospinal fluid (CSF) and chemotherapy dosing on relapse.
Main Methods:
- Retrospective analysis of 157 MB/PNET patients treated between 1981 and 1997.
- Evaluation of factors including age, gender, tumor size, CSF cytology, extent of resection, and treatment modalities (surgery, chemotherapy, radiotherapy).
- Statistical analysis to identify significant predictors of relapse.
Main Results:
- The presence of tumor cells in CSF at diagnosis was a significant predictor of relapse (P=0.004).
- Higher mean chemotherapy doses were associated with a lower risk of relapse (83.7% vs. 76.1%, P=0.0013).
- Chemotherapy administered after radiotherapy showed a trend towards improved outcomes (P=0.06).
Conclusions:
- Tumor cells in CSF are a significant risk factor for MB/PNET recurrence.
- Adequate chemotherapy dosing is essential for preventing relapse and improving treatment outcomes.
- Prolonged adjuvant chemotherapy following radiotherapy may reduce the risk of recurrence.